Donor antigen-specific regulatory T cell administration to recipients of live donor kidneys: A ONE Study consortium pilot trial
EC Guinan, L Contreras-Ruiz, K Crisalli… - American Journal of …, 2023 - Elsevier
Regulatory T cells (Tregs) can inhibit cellular immunity in diverse experimental models and
have entered early phase clinical trials in autoimmunity and transplantation to assess safety
and efficacy. As part of the ONE Study consortium, we conducted a phase I-II clinical trial in
which purified donor antigen reactive (dar)-Tregs (CD4+ CD25+ CD127 lo) were
administered to 3 patients, 7 to 11 days after live donor renal transplant. Recipients received
a modified immunosuppression regimen, without induction therapy, consisting of …
have entered early phase clinical trials in autoimmunity and transplantation to assess safety
and efficacy. As part of the ONE Study consortium, we conducted a phase I-II clinical trial in
which purified donor antigen reactive (dar)-Tregs (CD4+ CD25+ CD127 lo) were
administered to 3 patients, 7 to 11 days after live donor renal transplant. Recipients received
a modified immunosuppression regimen, without induction therapy, consisting of …